Beriate® P in the treatment of patients with haemophilia A: results of a long-term pharmacovigilance study.

[1]  P. Mannucci,et al.  EUHASS: The European Haemophilia Safety Surveillance system. , 2011, Thrombosis research.

[2]  M. Makris,et al.  Biovigilance and pharmacovigilance for haemophilia , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

[3]  V. Blanchette,et al.  Prophylaxis in the haemophilia population , 2010, Haemophilia.

[4]  R. Liesner,et al.  A United Kingdom Haemophilia Centre Doctors’ Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A , 2010, British journal of haematology.

[5]  Alan R. Cohen,et al.  Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. , 2007, The New England journal of medicine.

[6]  J. Ingerslev.  Pharmacovigilance studies in haemophilia , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

[7]  K. Kurnik,et al.  Continuous infusion of factor concentrates in children with haemophilia A in comparison with bolus injections , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[8]  J. Astermark,et al.  Consensus perspectives on prophylactic therapy for haemophilia: summary statement , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[9]  D. Grobbee,et al.  Prophylactic treatment for severe haemophilia: comparison of an intermediate‐dose to a high‐dose regimen , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[10]  D. Dingli,et al.  Continuous factor VIII infusion therapy in patients with haemophilia A undergoing surgical procedures with plasma‐derived or recombinant factor VIII concentrates , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[11]  A. Batorova,et al.  Intermittent injections vs. continuous infusion of Factor VIII in haemophilia patients undergoing major surgery , 2000, British journal of haematology.

[12]  C. Kessler,et al.  When should prophylactic treatment in patients with haemophilia A and B start?— The German experience , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

[13]  P. Mannucci,et al.  Modern treatment of haemophilia. , 1995, Bulletin of the World Health Organization.

[14]  H. Pettersson,et al.  A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs , 1994, Journal of internal medicine.

[15]  J. Vermylen,et al.  Factor VIII preparations: need for prospective pharmacovigilance , 1993, The Lancet.

[16]  S. Schulman,et al.  Adjusted dose continuous infusion of factor VIII in patients with haemophilia A , 1992, British journal of haematology.

[17]  H. Pettersson,et al.  Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and B , 1992, Journal of internal medicine.

[18]  R. Bona,et al.  Continuous infusion of monoclonal antibody‐purified factor VIII , 1991, American journal of hematology.

[19]  R. Weinstein,et al.  The use of continuous infusion of factor concentrates in the treatment of hemophilia , 1989, American journal of hematology.

[20]  A. Bloom.  Haemostasis and thrombosis , 1981 .